Seamless Therapeutics, a German-based biotechnology startup founded by Anne-Kristin Heninger, is taking gene editing to the next level with a groundbreaking approach to restoring health in patients with severe conditions. The company recently raised $12.5M in seed funding from Wellington Partners and Forbion, two leading investors in the field. Seamless Therapeutics' proprietary technology platform unlocks the reprogramming of site-specific recombinases, a highly versatile class of enzymes, enabling the development of a pipeline of novel treatments across a broad spectrum of indications.

According to Felix Lansing, Co-Founder and Chief Scientific Officer of Seamless Therapeutics, the company's modular platform has succeeded in reprogramming site-specific recombinases to any given target sequence, breaking down the existing hurdles of leveraging this potential best-in-class gene editing system to treat human disease. The company's pioneering approach has not gone unnoticed by investors. Karl Nägler, Ph.D., Managing Partner at Wellington Partners, says, "We are excited to support Seamless Therapeutics in its pursuit of taking a leadership position in the rapidly evolving gene editing arena." Dmitrij Hristodorov, Ph.D. Seamless Therapeutics' innovative platform has the potential to transform the future of healthcare and improve the lives of patients with severe conditions in a safe and precise manner.